Severe and multiple hypoglycemic episodes are associated with increased risk of death in ICU patients

*Critical Care* (2015) 19:153

doi:10.1186/s13054-015-0851-7

Pierre Kalfon (pkalfon@ch-chartres.fr)
Yannick Le Manach (Yannick.Lemanach@phri.ca)
Carole Ichai (ichai@unice.fr)
Nicolas Bréchot (nicolas.brechot@psl.aphp.fr)
Raphaël Cinotti (raphael.cinotti@chu-nantes.fr)
Pierre-François Dequin (dequin@med.univ-tours.fr)
Béatrice Riu-Poulenc (riu.b@chu-toulouse.fr)
Philippe Montravers (philippe.montravers@bch.aphp.fr)

Djilalli Annane (djilalli.annane@rpc.aphp.fr)
Hervé Dupont (dupont.herve@chu-amiens.fr)
Michel Sorine (Michel.Sorine@inria.fr)
Bruno Riou (bruno.riou@psl.aphp.fr)
on behalf of the CGAO-REA Study Group

Published online: 08 April 2015

**ISSN** 1364-8535
**Article type** Research
**Submission date** 25 December 2014
**Acceptance date** 2 March 2015
**Article URL** [http://dx.doi.org/10.1186/s13054-015-0851-7](http://dx.doi.org/10.1186/s13054-015-0851-7)

For information about publishing your research in BioMed Central journals, go to [http://www.biomedcentral.com/info/authors/](http://www.biomedcentral.com/info/authors/)
Severe and multiple hypoglycemic episodes are associated with increased risk of death in ICU patients

Pierre Kalfon1*
*Corresponding author
Email: pkalfon@ch-chartres.fr

Yannick Le Manach2
Email: Yannick.Lemanach@phri.ca

Carole Ichai3
Email: ichai@unice.fr

Nicolas Bréchot4
Email: nicolas.brechet@psl.aphp.fr

Raphaël Cinotti5
Email: raphael.cinotti@chu-nantes.fr

Pierre-François Dequin6
Email: dequin@med.univ-tours.fr

Béatrice Riu-Poulenc7
Email: riu.b@chu-toulouse.fr

Philippe Montravers8
Email: philippe.montravers@bch.aphp.fr

Djilalli Annane9
Email: djillali.annane@rpc.aphp.fr

Hervé Dupont10
Email: dupont.herve@chu-amiens.fr

Michel Sorine11
Email: Michel.Sorine@inria.fr

Bruno Riou12,13
Email: bruno.riou@psl.aphp.fr

on behalf of the CGAO-REA Study Group

1 Service de Réanimation polyvalente, Hôpital Louis Pasteur, CH de Chartres, Le Coudray, France
Abstract

Introduction

Using a randomized controlled trial comparing tight glucose control with a computerized decision-support systems and conventional protocols (post hoc analysis), we tested the hypothesis that hypoglycemia is associated with a poor outcome, even when controlling for initial severity.

Methods

We looked for moderate (2.2-3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia, multiple hypoglycemic events (n ≥ 3), and the other main components of glycemic control (mean blood glucose level and blood glucose coefficient of variation (CV)). The primary end-point
was 90-day mortality. We used both a multivariable analysis taking into account only variables observed at admission and a multivariable matching process (greedy matching algorithm, caliper width of $10^{-5}$ digit with no replacement).

**Results**

A total of 2,601 patients were analyzed and divided into three groups: no hypoglycemia (n = 1,474), moderate hypoglycemia (n = 874, 34%), and severe hypoglycemia (n = 253, 10%). Patients with moderate or severe hypoglycemia had a poorer prognosis as shown by a higher mortality rate (36% and 54% respectively, vs. 28%) and decreased number of treatment-free days. In the multivariable analysis, severe (OR 1.50, 95% CI 1.36-1.56, P = 0.043) and multiple hypoglycemic events (OR 1.76, 95% CI 1.31-3.37, P < 0.001) were significantly associated with mortality whereas blood glucose CV was not. Using multivariable matching, patients with severe (53 vs. 35%, P < 0.001), moderate (33 vs. 27%, P = 0.029), and multiple hypoglycemic events (46 vs. 32%, P < 0.001), had a higher 90-day mortality.

**Conclusion**

In a large cohort of ICU patients, severe hypoglycemia and multiple hypoglycemic events were associated with increased 90-day mortality.

**Trial registration**

Clinicaltrials.gov Identifier NCT01002482 Registered 26 October 2009.

**Introduction**

Stress hyperglycemia and insulin resistance are frequent in critically ill patients and associated with poor outcome [1,2]. As compared to permissive hyperglycemia, intensive insulin therapy targeting a tight low range for blood glucose has been shown to reduce in-hospital mortality in a single center randomized trial in critically ill surgical patients [3]. However, subsequent multicenter randomized controlled trials in broader intensive care unit (ICU) population did not find survival benefit [4-7] or suggested increased mortality [8]. In these studies a higher prevalence of hypoglycemia was associated with intensive insulin therapy. In diabetic patients, hypoglycemia is widely recognized as a severe adverse event, leading to neurological insult or death [9,10]. Such association is less clear in the ICU since some trials assessing tight blood glucose control observed an increased in hypoglycemia occurrence with [11,12] or without [4-7] significant increase in mortality. There is a clear association between severity of ICU patients and the occurrence of hypoglycemia [13] and this association may have been often underestimated when analyzing the possible link between hypoglycemia and mortality. Moreover, previous studies were associated with methodological concerns as they included events as covariates that may have been due to hypoglycemia [11,14], or because multivariate analyses may be subject of overfitting, because of the multiplicity of cofounders included in the model [15-17]. Therefore, the link between hypoglycemia and mortality remains a matter of debate, as well as its causality [18].

We used the large cohort of ICU patients included in our recent randomized study [7] to test the hypothesis that hypoglycemia is associated with a poor outcome, even when controlling for initial severity. For this purpose we used a multivariate analysis taking into account only
variables observed at admission. We also used a multivariate matching process, which is less sensitive to unknown bias variables and is considered as more powerful, approaching the ideal randomization that is not possible here [19]. We also tested the two other main components of glycemic control (mean blood glucose level and blood glucose variability) that are suspected to be also linked to mortality in ICU patient [20].

**Material and methods**

This is an ancillary study of the CGAO-REA trial (NCT01002482, Registered 26 October 2009), a non-blinded parallel-group randomized controlled trial involving adult patients admitted to ICUs and comparing tight glucose control with a clinical computerized decision-support systems (blood glucose range between 4.4 and 6.1 mmol/l) and conventional glucose control protocols (blood glucose levels inferior to 10 mmol/l), [7] and corresponds to a post hoc analysis. A subgroup analysis of patients with traumatic brain injury has also been published [21]. The study was approved by an ethical committee (Comité de Protection des Personnes, CCP de Tours, Tours, France). Written informed consent or delayed consent was obtained from each patient or a legal surrogate.

**Patients**

Adult patients who were assumed to require at least 3 days in the ICU were eligible for inclusion. We excluded moribund patients with imminent death or those for whom there were do-not-resuscitate orders or the attending physicians were not committed to full supportive care, patients admitted for treatment of diabetic ketoacidosis or hyperosmolar state, patients expected to be eating before the end of the day following the day of admission in the ICU, patients who had previously suffered hypoglycemia without documented full neurological recovery, and patients considered as being at high risk of suffering hypoglycemia. It was not mandatory that the patient experienced an episode of hyperglycemia within 24 hours after admission.

**Study design**

Within 24 hours after admission, patients were randomly assigned to undergo tight computerized glucose control or conventional blood glucose control [7]. Blood samples for glucose measurement were obtained by means of arterial catheters whenever possible; the use of capillary samples was discouraged. Blood glucose was measured with bedside glucose readers or preferentially with arterial blood gas analyzer devices when available. At least one blood glucose value per day was measured by the hospital central laboratory on a morning sample (morning laboratory blood glucose). Only the blood glucose values measured at the bedside (e.g. either with point-of-care glucose readers or with blood gas analyzers located in the ICU) were used uncorrected for the adaptation of insulin infusion rate. Each ICU used regular human insulin in saline with the same concentration (50 IU in 50 mL of 0.9% sodium chloride) with the use of a pump. A dedicated line for intravenous insulin infusion was encouraged to avoid occult administration of insulin or delay for effective application of a new insulin rate. Enteral feeding was attempted as early as possible. All other aspects of patient care, including nutritional management, were carried out at the discretion of the treating physicians.
At baseline, clinical characteristics, including the Simplified Acute Physiology Score (SAPS II) [22], presence of trauma, the McCabe score for the evaluation of the prognosis of the underlying disease [23] and the Sequential Organ Failure (SOFA) [24] were collected.

**Definition of hypoglycemia and blood glucose metrics**

Blood glucose control was assessed by morning laboratory blood glucose each day until ICU discharge or day 28. Because different numbers of measures per day were obtained in the two groups, we extracted only 4 blood glucose measurements per day, closest to 2:00, 8:00, 14:00, and 20:00, respectively. Severe hypoglycemia was defined as blood glucose < 2.2 mmol/l and moderate hypoglycemia was defined as blood glucose between 2.2 and 3.3 mmol/l, as previously described [7]. The number of hypoglycemic events was recorded in each patients and the density calculated (expressed as number of events per day of insulin administration and per day of ICU). We also recorded the mean, minimal, and maximal blood glucose readings during the intervention period, the standard deviation (SD) and coefficient of variation (CV) of blood glucose, and the total and daily doses of insulin. Blood glucose variability was considered as moderate (CV 0.20 to 0.39) or severe (CV >0.40) as previously described [16].

**Outcome measures**

Study primary outcome was death from any cause within 90 days after ICU admission. Secondary predefined outcomes were death within 28 days after ICU admission, 28-day-ICU-free days, 28-day-hospital-free days, 28-day-ventilator-free days (either mechanical ventilation or non-invasive ventilation), 28-day-free-of-catecholamines days, and 28-day-free-of renal replacement therapy, as previously described [7,25]. These 28-day-free-of-treatment days were calculated by subtracting the actual treatment duration in days from 28, with patients who died at day 28 or before being assigned 0 free-days. We also compared the following main glucose metrics: mean blood glucose and blood glucose CV [20].

**Statistical analysis**

Data are expressed as mean ± SD, median [25–75 interquartile], and number (percentage). Normality was assessed with the D’Agostino-Pearson omnibus test. Comparison of means was performed using the Student t test or analysis of variance and Newman-Keuls test, comparison of medians was performed using the Mann and Whitney test or Kruskall-Wallis test for multiple comparison, and comparison of proportions was performed using Fisher’s exact method with Bonferroni correction when appropriate. Using logistic regression and using all variables known at admission in ICU, we determined variables associated with mortality at 90 days and calculated odds ratios (OR) and their 95% confidence interval (CI). Co-linearity between variables was considered when r > 0.60 (Spearman coefficient matrix correlation). Calibration of the model was assessed using the Hosmer-Lemeshow test, and discrimination using the c-statistic. This model enables us to calculate the probability of death at 90 days. Then we conducted a multivariate analysis including all significant variables in the model (age, BMI, SAPS II score, SOFA score, McCabe score, and the cause of ICU admission) and by forcing the main variables of blood glucose metrics: severe and moderate hypoglycemia, number of hypoglycemic events (any type, 0 to 2 vs. ≥ 3), mean blood glucose level, blood glucose CV, and type of blood glucose control conventional vs. computerized) in the model.
To reduce the effects of confounding, matched populations of patients without hypoglycemia and patients with moderate or severe hypoglycemia were created using propensity score matching. The propensity model was constructed to match pairs of patients without hypoglycemia and hypoglycemic patients using a multivariable logistic model and a greedy matching algorithm with a 1:1 (moderate hypoglycemia) or 2:1 (severe hypoglycemia, multiple hypoglycemic events) ratio and a caliper width of $10^{-5}$ digit with no replacement. Propensity score matching is one of the propensity score methods used to mimic some of the characteristics of a randomized controlled trial [26]. Applied to the context of our observational study on hypoglycemic events, it consists in forming matched sets of hypoglycemic and non-hypoglycemic patients who share a similar value of the propensity score. In greedy matching within a specified caliper distance, a hypoglycemic patient is first selected at random; the patient without hypoglycemia whose propensity score is closest to that of this randomly selected hypoglycemic patient (with the further restriction that the absolute difference in the propensity scores of matched patients must be below the caliper distance) is chosen for matching to this hypoglycemic patient. This process is called greedy because at each step in the process, the nearest patient without hypoglycemia is selected for matching to the given hypoglycemic patient, even if that patient without hypoglycemia would better serve as a match for a subsequent hypoglycemic patient. This nearest patient without hypoglycemia is no longer available for a new match with another hypoglycemic patient (no replacement). If no patients without hypoglycemia had propensity scores that lay within the specified caliper distance of the propensity score of the hypoglycemic patient, this unmatched hypoglycemic patient would then be excluded from the matching process. All variables available at admission were included in the matching model. Patients without hypoglycemia and hypoglycemic patients, for whom no paired match was found, were discarded from the analysis. After matching, absolute standardized differences (ASD) were calculated to assess the similarity in pre-operative patient characteristics, and expressed as a percentage. An ASD above 10% was considered to represent meaningful difference [27]. In order to estimate the association of hypoglycemia and mortality in population predefined subgroups, the same analysis was then conducted in diabetic and non-diabetic patients, and in the two groups (conventional vs. computerized blood glucose control).

All P values were two-tailed and a P value of less than 0.05 was considered significant. Statistical analysis was performed using NCSS 7.0 software (Statistical solutions Ltd., Cork, Ireland) and R 3.1.1 software (www.cran.r-project.org, last date accessed August 9, 2014).

**Results**

Among the 2,684 randomized patients, 1,351 were assigned to computerized and 1,333 to conventional blood glucose control. Thirty-six patients were discarded from any analysis (35 withdrew consent and 1 was included twice). Among the 2,648 remaining patients, 47 were discarded because important data concerning blood glucose measurement were lacking. Thus, 2,601 patients were analyzed (Figure 1).

**Figure 1 Flow chart of the study.**

Hypoglycemia ($<3.3$ mmol/l) occurred in 1127 (43%, 95% CI 41-45%) patients. The density of hypoglycemia was 0.30 events per day of insulin therapy and 0.15 events per day in the ICU. Severe hypoglycemia ($<2.2$ mmol/l) occurred in 253 (10%, 95% CI 9-11%) patients. The density of severe hypoglycemia was 0.037 events per day of insulin therapy and 0.020
events per day in the ICU. Moderate hypoglycemia (2.2 to 3.3 mmol/l) occurred in 874 (34%, 95% CI 32-35%) patients. The density of moderate hypoglycemia was 0.26 events per day of insulin therapy and 0.13 events per day in the ICU. Figure 2 shows the distribution of the number of hypoglycemic events (severe, moderate, any type) per patient. Multiple hypoglycemic events (any type, n ≥ 3) occurred in 482 (19%, 95% CI 17-20%) patients and their 90-day mortality was significantly increased as compared to patients with less hypoglycemic events (51 vs. 29%, P < 0.001). Blood glucose variability was available in 2,507 patients. Moderate blood glucose variability (CV 0.20 to 0.39) occurred in 1,447 (56%, 95% CI 54-58%) patients, and severe blood glucose variability (CV ≥0.40) occurred in 238 (9%, 95% CI 8-10%) patients. The 90-day mortality was higher in patients with moderate or severe blood glucose variability as compared to controls (36 vs. 24%, P < 0.001; 42 vs. 24%, P < 0.001, respectively). There was no significant difference in 90-day mortality between moderate and severe blood glucose variability (P = 0.21).

Figure 2 Distribution of the number of hypoglycemic events (A: severe (<2.2 mmol/l) B: moderate (2.2 to 3.3 mmol/l); C: any type (<3.3 mmol/l) per patient.

Patients were divided into three groups: No hypoglycemia (n = 1,474), Moderate hypoglycemia (n = 874), and Severe hypoglycemia (n = 253) (Figure 1). The main characteristics of patients in these 3 groups are shown in Table 1. Patients with moderate or severe hypoglycemia had worse outcome (Table 1). However, they had more severe illness as shown by higher SAPS II and SOFA scores. They had more underlying diabetes, were more frequently mechanically ventilated, on vasopressor therapy, or on renal replacement therapy (Table 1). Blood glucose data are shown in Table 2. Patients with moderate or severe hypoglycemia had higher blood glucose variability (SD and CV) and lower mean blood glucose levels (Table 2). Comparable results were noted when considering patients with multiple hypoglycemic events (Table 1).

Table 1 Baseline characteristics and outcome of the study patients

| Variables                        | No hypoglycemia (n = 1,474) | Moderate hypoglycemia (n = 874) | Severe hypoglycemia (n = 253) | Multiple hypoglycemic events (n = 482) |
|----------------------------------|-----------------------------|-------------------------------|-------------------------------|---------------------------------------|
| Age, yr                          | 61 (17)                     | 63 (16)                       | 62 (15)                       | 63 (15)                               |
| Male sex, n (%)                  | 963/1,474 (65)              | 553/874 (63)                  | 163/253 (64)                  | 320/482 (65)                          |
| Weight, kg                       | 80 (21)                     | 75 (18)*                      | 74 (20)*                      | 74 (18)*                              |
| Body mass index, kg.m^-2         | 27.5 (6.7)                  | 26.2 (5.9)*                   | 25.6 (6.1)*                   | 25.9 (6.0)*                           |
| SAPS II score                    | 46 [34–61]                  | 52 [40–67]*                   | 59 [46–74]*†                  | 65 [55–75]*                           |
| SOFA score                       | 7 [4–10]                    | 8 [5–11]*                     | 10 [7–13] *†                  | 10 [7–12]*                            |
| McCabe score                     | 1 [1–2]                     | 1 [1–2]                       | 1 [1–2]                       | 1 [1–2]                               |
| Type of patients                 |                             |                               |                               |                                       |
| Medical                          | 872/1,474 (59)              | 161/874 (60)                  | 161/253 (64)                  | 281/482 (60)                          |
| Scheduled surgical               | 457/1,474 (31)              | 75/874 (29)                   | 75/253 (30)                   | 158/482 (30)                          |
| Emergency surgical               | 145/1,474 (10)              | 17/874 (11)                   | 17/253 (7)                    | 53/482 (10)                           |
| History of diabetes mellitus, n (%) | 266/1,474 (18)           | 189/874 (22)                  | 70/253 (28)*                  | 131/482 (27)                          |
| Type 1 diabetes, n (%)           | 38/1,474 (3)                | 32/874 (4)                    | 14/253 (6)                    | 22/481 (5)                            |
| Type 2 diabetes, n (%)           | 228/1,474 (15)              | 157/874 (18)                  | 55/253 (22)                   | 108/481 (22)                          |
| Nor determined                   |                             |                               |                               |                                       |
| Previous treatment               | 118/1,474 (5)               | 21/873 (8)                    | 21/253 (8)                    | 35/482 (7)                            |
| Insulin*, n (%)                  | 114/1,474 (5)               | 18/873 (7)                    | 18/253 (7)                    | 28/482 (6)                            |
| Antidiabetic drugs, n (%)        |                             |                               |                               |                                       |
| Plasma creatinine, μmol.L^-1     | 133 (140)                   | 150 (133)                     | 166 (158)*                    | 169 (147)*                            |
| Initial treatment in the ICU     |                             |                               |                               |                                       |
Table 2 Blood glucose metrics

| Variables                        | No hypoglycemia (n = 1,474) | Moderate hypoglycemia (n = 874) | Severe hypoglycemia (n = 253) | Multiple hypoglycemic events (n = 482) |
|----------------------------------|-----------------------------|---------------------------------|------------------------------|--------------------------------------|
| Initial blood glucose, mmol.L⁻¹ | 8.9 (4.0)                   | 9.6 (4.6)*                      | 9.8 (5.5)*                   | 9.7 (4.2)*                           |
| Mean morning blood glucose, mmol.L⁻¹ | 7.2 (2.3)                | 6.8 (1.6)*                      | 6.8 (1.8)*                   | 6.7 (1.8)*                           |
| Mean blood glucose, mmol.L⁻¹    | 7.2 (1.7)                   | 6.7 (1.2)*                      | 6.8 (1.5)*                   | 6.6 (1.2)*                           |
| Maximum blood glucose, mmol.L⁻¹ | 11.3 (1.4)                  | 12.8 (4.1)*                     | 14.6 (5.1)*†                 | 14.2 (4.9)*                          |
| Minimum Blood glucose, mmol.L⁻¹ | 4.6 (1.4)                   | 2.9 (0.3)                       | 1.7 (0.4)                    | 2.2 (0.6)                            |
| Blood glucose SD, mmol.L⁻¹      | 1.5 (1.0)                   | 2.0 (1.0)*                      | 2.4 (1.3)*†                  | 2.2 (1.1)*                           |
| Blood glucose CV                | 0.20 [0.15–0.26]            | 0.27 [0.22–0.34]*               | 0.32 [0.25–0.39]*†           | 0.31 [0.25–0.38]*                    |
| Blood glucose CV >0.20         | 715/1428 (50%)             | 735/873 (84%)*                  | 235/253 (93%)*†              | 452/479 (94%)*                       |
| Total insulin dose (IU)        | 121 [38–344]               | 348 [123–801]*                  | 442 [129–986]*               | 534 [201–1109]*                      |
| Daily insulin dose (IU.day⁻¹)  | 19 [4–41]                  | 34 [15–58]*                     | 35 [17–59]*                  | 38 [20–61]*                          |
| Day with insulin               | 5 [3–11]                   | 9 [4–17]*                       | 10 [5–20]*†                  | 12 [6–22]*                           |
| Number of blood glucose measurements | 28 [16–56]                | 44 [24–80]*                     | 52 [28–104]*†                | 50 [32–108]*                         |
| Number of moderate hypoglycemia |                            | 3 [1–6]                         | 4 [3–6]                      |                                      |
| Number of severe hypoglycemia   |                            | 2 [1–3]                         | 1 [1–2]                      | 0 [0–1]                              |
| Number of hypoglycemic events (any type) |                        | 5 [3–8]                         | 4 [3–7]                      |                                      |
| Hypoglycemic events (any type) ≥3 |                            | 2 [1–3]                         | 197 (77%)                    | 482 (100%)                           |

Data are expressed as mean (SD), median [25–75 interquartile], and No. (%). CV: coefficient of variation.

*: P < 0.05 vs No hypoglycemia group; †: P < 0.05 vs Moderate hypoglycemia group (only for Severe hypoglycemia group).

In the multivariable model, 6 variables were significantly associated with 90-day mortality: age, BMI, SAPS II score, SOFA score, McCabe score, and the cause of ICU admission. The discrimination of the model was appropriate (c-statistic 0.745) as well as its calibration (Hosmer-Lemeshow test, Chi² = 10.12, P = 0.34). When added to this model, severe hypoglycemia, multiple hypoglycemic events, and mean blood glucose level variables were significantly associated with 90-day mortality in contrast to moderate hypoglycemia and blood glucose CV (Table 3). We performed then a sensitivity analysis by excluding patients allocated to computerized blood glucose control and the variables severe hypoglycemia (OR 2.08 95% CI 1.12–3.86, P = 0.02) and mean blood glucose level (OR 1.10, 95% CI 1.00–1.21, P = 0.045) remained significantly associated with 90-day mortality whereas the variables
moderate hypoglycemia (OR 134, 95% CI 0.94-1.91, P = 0.11) and multiple hypoglycemic events (OR 1.42, 95% CI 0.85-2.37, P = 0.18) were not.

### Table 3 Multivariable analysis of variables associated with 90-day mortality (n = 2,312)

| Variables                  | Odds ratio [95% IC] | P value |
|----------------------------|---------------------|---------|
| Age (per 1 year)           | 1.024 [1.017-1.031] | <0.001  |
| Body mass index (per 1 kg.m\(^{-2}\)) | 0.979 [0.963-0.995] | 0.008   |
| SAPS II score (per 1 point) | 1.019 [1.012-1.025] | <0.001  |
| SOFA score (per 1 point)   | 1.086 [1.053-1.120] | <0.001  |
| McCabe score (per 1 point) | 1.587 [1.357-1.885] | <0.001  |
| Type of patient            |                     |         |
| Medical                    | 1                   |         |
| Scheduled surgical         | 0.663 [0.532-0.827] | <0.001  |
| Emergency surgical         | 0.460 [0.321-0.657] | <0.001  |
| Moderate hypoglycemia      | 1.114 [0.865-1.436] | 0.40    |
| Severe hypoglycemia        | 1.571 [1.055-2.339] | 0.03    |
| Number of hypoglycemic events ≥3 | 1.834 [1.361-2.471] | <0.001  |
| Mean blood glucose (per 1 mmol.L\(^{-1}\)) | 1.086 [1.010-1.168] | 0.03    |
| Blood glucose CV <0.20     | 1                   |         |
| Blood glucose CV 0.20-0.39 | 1.155 [0.906-1.472] | 0.24    |
| Blood glucose CV ≥0.40     | 1.041 [0.698-1.552] | 0.84    |
| Computerized blood glucose control | 0.786 [0.639-0.958] | 0.02    |

CV: coefficient of variation; OR: odds ratio; CI: confidence interval; c-index: 0.757.

Using multivariable matching, we matched each patient with severe hypoglycemia with 2 patients without hypoglycemia, each patient with moderate hypoglycemia with 1 patient without hypoglycemia, and each patient with multiple hypoglycemic events with 2 patients without hypoglycemia. The proportion of discarded patients were 27% in the moderate hypoglycemia group, 21% in the severe hypoglycemia and 51% in the multiple hypoglycemic events groups. After matching the highest ASD was 5.9%. Table 4 shows the comparison between these matched groups of patients. Although the matching process provided two groups that were comparable for severity, patients with moderate or severe hypoglycemia and those with multiple hypoglycemic events had a poorer prognosis as shown by a higher 90-day mortality and decreased number of treatment-free days (Table 4).

### Table 4 Comparison of outcome and blood glucose metrics in matched groups

#### Matching for moderate hypoglycemia

| Variables                  | No hypoglycemia (n = 640) | Moderate hypoglycemia (n = 640) | P value |
|----------------------------|---------------------------|---------------------------------|---------|
| Probability of death       | 0.28 (0.19)               | 0.28 (0.18)                     | 0.66    |
| Outcome                   |                           |                                 |         |
| RRT free days             | 28 [21–28]                | 28 [7–28]                       | 0.06    |
| Catecholamines free days  | 25 [17–27]                | 24 [2–27]                       | <0.001  |
| Mechanical ventilation free days | 20 [0–25]                 | 15 [0–23]                       | <0.001  |
| ICU free days             | 19 [0–24]                 | 13 [0–22]                       | <0.001  |
| Mortality 28 days         | 137 (21%)                 | 151 (24%)                       | 0.38    |
| Mortality 90 days         | 176 (27%)                 | 213 (33%)                       | 0.029   |
| Blood glucose metrics     |                           |                                 |         |
| Mean blood glucose        | 7.2 (1.6)                 | 6.6 (1.1)                       | <0.001  |
| Blood glucose CV          | 0.21 (0.09)               | 0.28 (0.09)                     | <0.001  |
| Insulin dose (IU.day\(^{-1}\)) | 22 [6–43]                 | 35 [5–59]                       | <0.001  |

#### Matching for severe hypoglycemia

| Variables                  | No hypoglycemia (n = 366) | Severe hypoglycemia (n = 199) | P value |
|----------------------------|---------------------------|-------------------------------|---------|
| Probability of death       | 0.32 (0.19)               | 0.35 (0.19)                    | 0.12    |
| Outcome                   |                           |                                |         |
| RRT free days             | 28 [0–28]                 | 24 [0–28]                      | <0.001  |
| Catecholamines free days  | 24 [0–26]                 | 18 [0–25]                      | <0.001  |
| Mechanical ventilation free days | 17 [0–24]                 | 18 [0–25]                      | <0.001  |
| ICU free days             | 17 [0–24]                 | 0 [0–28]                       | <0.001  |
| Mortality 28 days         | 102 (28%)                 | 75 (38%)                       | 0.017   |
| Mortality 90 days         | 17 [0–24]                 | 106 (53%)                      | <0.001  |

#### Matching for multiple hypoglycemic events

| Variables                  | No hypoglycemia (n = 445) | Multiple hypoglycemic (n = 234) | P value |
|----------------------------|---------------------------|---------------------------------|---------|
| Probability of death       | 0.32 (0.20)               | 0.32 (0.19)                     | 0.81    |
| Outcome                   |                           |                                 |         |
| RRT free days             | 23 [7–41]                 | 35 [19–56]                      | <0.001  |

CV: coefficient of variation; OR: odds ratio; CI: confidence interval; c-index: 0.757.
**RRT free days** 28 [0–28] 28 [0–28] 0.06
**Catecholamines free days** 24 [0–26] 19 [0–25] <0.001
**Mechanical ventilation free days** 18 [0–24] 5 [0–18] <0.001
**ICU free days** 17 [0–24] 1 [0–17] <0.001
**Mortality 28 days** 115 (26%) 64 (27%) 0.71
**Mortality 90 days** 141 (32%) 108 (46%) <0.001

**Blood glucose metrics**

- **Mean blood glucose** 7.0 (1.5) 6.7 (1.0) <0.001
- **Blood glucose CV** 0.24 (0.10) 0.31 (0.09) <0.001
- **Insuline dose (IU.day⁻¹)** 26 [8–49] 41 [22–63] <0.001

Data are expressed as mean (SD), median [25–75 interquartile], and No. (%).

ICU = intensive care unit; RRT: renal replacement therapy; CV = coefficient of variation.

The association of severe and moderate hypoglycemia, and multiple hypoglycemic events with 90-day mortality was not different among the pre-specified subgroup analyses (non-diabetic patients, computerized decision-support systems and conventional glucose control), except for diabetic patients (Figure 3).

**Figure 3 Sub group analysis.** Odds ratio (OR) and 95% confidence interval (CI) for death at 90 days associated with moderate (full square) or severe (full circle) hypoglycemia or multiple (n ≥ 3) hypoglycemic (full triangle) events in total population and in matched subgroups according to treatment assignment (conventional vs. computerized decision support system, CDSS) and diabetic status (diabetic vs. non diabetic). Matching was performed using propensity score and a ratio of 2:1 for severe hypoglycemia and 1:1 for moderate hypoglycemia and multiple hypoglycemic events. The size of symbols is related to the number of patients (N) retained in the matching process.

**Discussion**

In this study, in a large cohort of ICU patients and using two different statistical approaches, we observed that both severe hypoglycemia and multiple hypoglycemic events were associated with increased risk of death. Blood glucose CV was not associated with mortality.

From a methodological and clinical point of view, we considered that it was important to perform the best possible adjustment for severity but using only variables observed at ICU admission. In contrast to some previous studies [11,28], we avoided to include any post ICU admission variable, such as the ICU length of stay because, if hypoglycemia has intrinsic deleterious effects, it should have been able to also impact these variables. We observed indeed that hypoglycemia was associated with increased ICU length of stay and use of mechanical ventilation, catecholamines, and renal replacement therapy, even when adjusting for initial severity (Tables 3 and 4). Although many studies found an association between hypoglycemia and mortality [11-17,28], others did not [14,29]. Using two different statistical approaches, our study confirms this association between hypoglycemia and mortality, at least when considering patients with severe hypoglycemia and multiple hypoglycemic events (Tables 3 and 4). Matching using propensity score is increasingly used in the medical literature [30] and has been shown to perform better than multivariable logistic regression in many situations [19]. In our study, these two approaches lead to consistent estimates of increased 90-day mortality associated with hypoglycemia. The magnitude of the increased risk of death observed in our study is also consistent with those previously reported [11,16,17,25,31].
There are three recognized domains of blood glucose metrics, mean blood glucose level, hypoglycemia, and blood glucose variability and all of them have been suspected to be linked to mortality in critically ill patients [13,20]. An important difficulty arises because all these variables are associated with initial severity in ICU patients and are significantly correlated one with the other, mathematically and probably clinically. Moreover, diabetic status is thought to modulate these relations [28] and the dose of insulin may also be considered as a fourth domain since a high dose of insulin may indicate a high degree of insulin resistance (which is also linked to illness severity) [32] and/or may be associated with non-glucose related therapeutic effects of insulin [33]. Consequently, there is some debate concerning the respective role of the different main domains of blood glucose metrics. Our study provides some evidence that blood glucose variability is less important than hypoglycemia. First, we did not observe a dose–response relationship for 90-day mortality with CV, using either a crude or adjusted analysis. Second, after adjusting for initial severity, blood glucose CV was not significantly associated with mortality (Table 3).

Although we performed the best adjustment possible using variables associated with initial severity, a causal relationship between hypoglycemia and mortality cannot be proven in such an observational study [34]. Nevertheless, some arguments are in favor of the existence of a causal relationship in an observational study, at least partially [35]. Among them (strength and consistency of the association, specificity, temporal relationship, plausibility, coherence, experiment, analogy), the NICE-SUGAR investigators have already evidenced specificity since the association was strongest for death from distributive shock [13]. As previously observed [11,13,14,17,28,31], we observed a dose–response relationship as severe hypoglycemia was associated with higher rates of death than was moderate hypoglycemia or the occurrence of multiple hypoglycemic events. The fact that blood glucose variability did not seem to be associated with mortality is an important point, which reinforces the hypothesis that hypoglycemia (at least severe and/or multiple) is deleterious. It may be also an argument against the hypothesis that the harm of hypoglycemia comes instead from its rapid correction leading to rebound hyperglycemia [13]. As previously reported [28], our study also confirms that diabetic patients may behave differently (Figure 3) but the small sample size of this group precludes definite conclusion.

Our study may enable us to reanalyze our previous published trial on tight blood glucose control which was characterized by a significant decrease in mean blood glucose with a significant increase in hypoglycemia rate without any impact on mortality [7]. It should be pointed out that such discrepancy between mortality rate (unchanged) and hypoglycemia rate (increased) was also observed in all previous major trials [4-6] except one [8], excluding the first trial performed during an era without any blood glucose control performed in the control group [3]. This discrepancy was also confirmed by the more recent meta-analysis [36]. Considering that hypoglycemia may be both a marker of severity and a deleterious event, two different hypotheses can be evoked in our trial [7]. First, the benefit of the improvement in blood glucose control may have been masked by the deleterious effects of hypoglycemia. Second, if hypoglycemia is only a marker of illness severity, tight blood glucose may have induced iatrogenic hypoglycemia, which may not be associated with higher mortality rate. It is not possible to draw definite conclusion and the two hypotheses may not be exclusive. Anyway, since many arguments suggest that hypoglycemia, at least severe and/or multiple ones, may be, at least partially, causally associated with mortality, clinicians and caregivers should continue to avoid, detect, and treat hypoglycemia, particularly when severe and/or repeated. It should be pointed out that we were not able to differentiate iatrogenic (related to
insulin administration) and spontaneous hypoglycemic events whereas the last one is thought to be more strongly associated with mortality but with possible less causality link [37]. Our study provides additional arguments to reduce or suppress hypoglycemic events induced by insulin protocols. Indeed, although most recommendations or guidelines have recently advocated for a higher glucose range target in the ICU based on recent meta-analyses showing a strong association between the glucose range targeted in insulin protocols and the risk for hypoglycemia, our study should lead to optimization the quality of glycemic control by improving the algorithms embedded in glucose controllers that calculate insulin rates to avoid hypoglycemia, especially in situations where the patient is exposed to variable insulin resistance, rather than by simply increasing the blood glucose target. In other words, minimizing occurrence and recurrence of hypoglycemic events seems more clinically relevant than choosing a high blood glucose target. It has already been demonstrated that an advanced protocol may both decrease the average blood glucose level and reduce the incidence of hypoglycemic events [38]. Further studies will be required to develop the high-performance glucose controllers in the ICU and to determine the best compromise between individualized blood glucose targets and the risk of hypoglycemia. Finally, whatever the causal link between hypoglycemia and mortality, prevention of hypoglycemic events is needed in the ICU because the occurrence of severe hypoglycemia is a priori associated with an increase in nurse workload (via additional time required for administering glucose in cases of severe hypoglycemia, which subsequently increases the risk of hyperglycemic rebound and creates a need for more frequent blood glucose monitoring after the hypoglycemic event [in the absence of continuous blood glucose monitoring system]).

In the same manner, our database did not enable us to assess the attributable mortality by incorporating the evolution in severity of illness during the ICU stay and using causal inference methods [39].

The strengths of our study are its size, its prospective and multicentric nature with a high proportion of patients treated with insulin (98%), a low mean blood glucose level (7.2 mmol/l) within the actual recommended target [40], and a high proportion of patients still in the ICU on the third day (94%). The initial high severity of our patients is shown by the high severity scores (median SAPS2 51, median SOFA 8) and the high mortality rate (33%) [7].

Our study has several limitations. First, sampling of blood glucose was intermittent and thus it is possible that some patients had undetected hypoglycemia. Second, another limitation is the absence of data regarding nutritional intakes. Third, the fact that our cohort comprises two randomized groups with different methods of blood control may also be considered as a limitation. Nevertheless, the use of a computerized decision support system seemed not to have interfered with our results, except for the role of moderate hypoglycemia since the association between moderate hypoglycemia and mortality was different between the two randomized groups (Figure 3). Fourth, the diabetic status of our patients was not precisely determined using measurement of blood glucose after provoked hyperglycemia or glycated hemoglobin measurement and thus we did not identify patients with prediabetic or occult diabetic status. In ICU patients, hyperglycemia seems to be not associated with significant increase in mortality in the subgroup of patients with premorbid hyperglycemia [41] but information is lacking considering hypoglycemia. Fifth, in ICU patients, severity of hypoglycemic events is usually defined by a biological threshold without possibility to precisely record clinical signs and this should also be considered as a limitation, as well as the lack of recording of the duration of the hypoglycemic events and the possible associated rebound in blood glucose levels. Sixth, we did not test all possible metrics of blood glucose
variability but no significant difference has been shown between them [20]. Lastly, since we included only adult patients, our results may not apply to a pediatric population [42].

**Conclusion**

In a large cohort of ICU patients, and using two different but concordant statistical approaches, we observed that severe hypoglycemia and multiple hypoglycemic events were associated with increased risk of death at 90 days. In contrast, blood glucose variability was not associated with 90-day mortality.

**Key messages**

- Severe hypoglycemia (<2.2 mmol/l) is associated with increased risk of death at 90 days in critically ill patients
- Multiple hypoglycemic episodes (at least 3 of any type of hypoglycemia, severe or moderate [2.2 to 3.3 mmol/l]) are associated with increased risk of death at 90 days in critically ill patients

**Abbreviations**

ASD, Absolute standardized difference; CI, Confidence interval; CV, Coefficient of variation; ICU, Intensive care unit; OR, Odds ratio; SD, Standard deviation; SOFA, Sequential organ failure assessment; SAPS II, Simplified acute physiology score

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

Dr. PK, YLM, and BR had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. PK and BR participated in the study concept and design. Drs. PK, CI, NB, RC, PFD, BR-P, PM, DA, and HD participated in the acquisition of data. Drs. PK, BR, CI, PFD, PM, DA, HD, and Mr. MS participated in the analysis and interpretation of data. Drs. PK, YLM, CI, MS, DA, and BR participated in the drafting of the manuscript and the critical revision of the manuscript for important intellectual content. Drs. BR and YLM performed the statistical analysis. Dr. PK obtained funding. Drs. PK, CI, PFD, PM, DA, HD, BR, and Mr. MS participated in the administrative, technical, or material support. The study supervision was performed by Dr. PK. All the authors read and approved the manuscript.

**Acknowledgements**

The CGAO-REA study was supported, in part, by the Société Française d’Anesthésie et de Réanimation (SFAR) and Baxter Healthcare Corporation. The study sponsor was Centre Hospitalier de Chartres, France. Dr. Kalfon is thankful for receiving the “Grand prix pour la Recherche 2008” from the Société Francaise d’Anesthésie et de Réanimation (SFAR)
supporting the CGAO-REA study. We gratefully thank all members of the nursing staff of each participating ICU for their strong involvement and motivation in the study.

We dedicated this article to the memory of Xavier Leverve, MD, PhD, who did not live to see the result of this study.

**Hospitals and principal investigators:** CHU d’Amiens, Amiens, Réanimation médico-chirurgicale (Dr Hervé Dupont, Dr François Tinturier); Hôpital Haut-Levesque, CHU de Bordeaux, Pessac, Service Anesthésie réanimation I (Dr Alexandre Ouattara), and Service Anesthésie Réanimation II Chirurgie digestive (Dr Catherine Fleureau, Dr Hadrien Roze); AP-HP, CHU Bicêtre, Bicêtre, Réanimation médicale (Dr David Osman, Dr François Richard); AP-HP, Hôpital Jean Verdier, Bobigny, Réanimation médico-chirurgicale (Dr Alexandre Avenel, Dr Roland Amathieu); Hôpital Saint-Camille, Bry/Marne, Réanimation polyvalente (Dr Anne-Sophie Le Floch, Dr Jean-François Loriferne); Hôpital Louis Pasteur, CH de Chartres, Le Coudray, Réanimation polyvalente (Dr Olivier Gontier, Dr Teodora Cirilovic, Dr Pierre Kalfon); CH de Châteauroux, Châteauroux, Réanimation polyvalente (Dr Michel Hira); Clinique des Cèdres, Cornebarrieu, Réanimation polyvalente (Dr Patrick Blanchet); Hôpital Victor Jousselin, CH de Dreux, Réanimation médicale (Dr Alexandre Conia); AP-HP, Hôpital Raymond Poincaré, Garches, Réanimation polyvalente (Dr Virginie Maxime, Dr Djillali Annane); CH départemental de Vendée, La Roche/Yon, Réanimation polyvalente (Dr Maud Fiancette, Dr Jean Reignier); CH de Mantes-La-Jolie, Mantes-La-Jolie, Réanimation polyvalente (Dr Christophe Lenclud, Dr Eric Barré); Hôpital La Timone, CHU de Marseille, Service d’Anesthésie Réanimation 1 (Dr Emmanuel Cantais, Dr Lionel Velly, Dr Nicolas Bruder); Hôpital Ambroise Paré, Marseille, Réanimation polyvalente, and Hôpital Paul Desbief, Marseille, Réanimation polyvalente (Dr Thomas Signouret); Hôpital Lapeyronie, CH de Montpellier, Montpellier, Réanimation (Dr Xavier Capdevila, Dr Jonathan Charbit, Dr Karim Lakhal); Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, Réanimation (Dr Jean-Marc Delay, Dr Samir Jaber, Dr Gérald Chanaques); Hôpital Laennec, CHU Nantes, Nantes, Réanimation chirurgie cardiaque et thoraco-vasculaire (Dr Raphaël Cinotti, Dr Bertrand Rozec, Dr Jean-Christophe Rigal); Hôpital Saint-Roch, CHU de Nice, Nice (Dr Carole Ichai, Dr Jean-Christophe Orban); AP-HP, CHU Bichat, Paris, Réanimation chirurgicale (Dr Guillaume Dufour, Dr Philippe Montravers, Dr Mathieu Desmard) and Réanimation (Dr Bruno Mourvillier); AP-HP, CHU Pitié Salpêtrière, Paris, Réanimation médicale, Institut de cardiologie (Dr Nicoals Brechet, Dr Jean Chastre, Dr Antoine Landivier; and Réanimation médicale (Dr Julien Mayaux, Dr Alexandre Duguet); CH de Pau, Pau, Réanimation médico-chirurgicale (Dr Paul Bonneil, Dr Jean-Noël Drault, Dr William Picard); Hôpital René Dubos, CH de Pontoise, Pontoise, Réanimation Médicale (Dr Eric Boulet, Dr Jack Richcoeur); CHU de Rouen, Rouen, Réanimation chirurgicale (Dr Gaëlle Demeillers-Pfister, Dr Philippe Gouin, Dr Benoit Veber); Hôpital Foch, Suresnes, Réanimation chirurgie cardiaque (Dr Thierry De Lentecker, Dr Mathieu Debauche); and Réanimation médicale (Dr Richard Galliot, Dr Anne-Gaëlle Si Larbi, Dr Florent Perin-Dureau; Hôpital Font-Pré, CH de Toulon, Toulon, Réanimation polyvalente (Dr Gaëlle Corno, Dr Jacques Durand-Gasselin); Hôpital Purpan, CHU Toulouse, Réanimation polyvalente (Dr Béatrice Riu-Poulen, Dr Michèle Genestal); Hôpital Rangueil, CHU de Toulouse, Réanimation médicale (Dr Pierre Cougot, Dr Hélène Gonzalez); CHU de Tours, Tours, Réanimation médicale (Dr Pierre-François Dequin, Dr Stéphane Ehmann, Dr Denis Garrot, Dr Emmanuelle Mercier); Hôpital André Mignot, CH de Versailles, Versailles, Réanimation médico-chirurgicale (Dr Mathieu Henri-Lagarrigue, Dr Jean-Pierre Bedos).

**Trial Steering Committee:** Dr Bruno Riou (chair), Dr Pierre Kalfon (lead investigator), Dr Djillali Annane, Dr Jean Chastre, Dr Pierre-François Dequin, Dr Hervé Dupont, Bruno Giraud, Alexandre Guerrini, Dr Carole Ichai, Dr Philippe Montravers, Michel Sorine.
Independent Data and Safety Monitoring Committee: Dr Jean-Charles Preiser (chair), Dr Francis Bonnet, Dr René Chiolero, Dr Xavier Leverve†, Dr Claude Martin.

References

1. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;373:1798–807.

2. Lena D, Kalfon P, Preiser JC, Ichai C. Glycemic control in the intensive care unit and during the postoperative period. Anesthesiology. 2011;114:438–44.

3. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.

4. van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters P, van Wijngaarden E, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.

5. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.

6. Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35:1738–48.

7. Kalfon P, Giraudieu B, Ichai C, Guerrini A, Brechot N, Cinotti R, et al. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. Intensive Care Med. 2014;40:171–80.

8. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.

9. McCoy RG, Shah ND, Van Houten HK, Wermers RA, Ziegenfuss JY, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897–901.

10. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Action to control cardiovascular risk in diabetes study group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

11. The NICE-SUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108–18.

12. Meyfroidt G, Keenan DM, Wang X, Wouters PJ, Veldhuis JD, Van den Berghe G. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. Crit Care Med. 2010;38:1021–9.
13. Krinsley JS, Schultz MJ, Spronk PE, Harmsen RE, van Braam HF, van der Sluijs JP, et al. Mild hypoglycemia is independently associated with increased mortality in the critically ill. Crit Care. 2011;15:R173.

14. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med. 2008;36:3190–7.

15. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010;85:217–24.

16. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38:838–42.

17. Mowery NT, Guillamondegui OD, Gunter OL, Diaz JJ, Collier BR, Dosset LA, et al. Severe hypoglycemia while on intensive insulin therapy is not an independent predictor of death after trauma. J Trauma. 2010;68:342–7.

18. Finfer S. Hypoglycemia in critically ill adults-association yes, causality not proven. Crit Care. 2011;15:1012.

19. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158:280–7.

20. Mackenzie IM, Whitehouse T, Nightingale PG. The metrics of glycaemic control in critical care. Intensive Care Med. 2011;37:435–43.

21. Cinotti R, Ichai C, Orban JC, Kalfon P, Feuillet F, Roquilly A, et al. Effects of tight computerized glucose control on neurological outcome in severely brain injured patients: A multicenter sub-group analysis of the randomized-controlled open-label CGAO-REA study. Crit Care. 2014;18:498.

22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.

23. McCabe WR, Jackson GG. Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med. 1962;110:847–81.

24. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.

25. Rubenfeld GD, Angus DC, Pinsky MR, Curtis JR, Connors Jr AF, Bernard GR. Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. Am J Respir Crit Care Med. 1999;160:358–67.
26. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.

27. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportion in observational studies. Pharm Stat. 2011;10:150–61.

28. Krinsley JS, Egi M, Kiss A, Devendra AN, Schuetz P, Maureer PM, et al. Diabetes status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care. 2013;17:37.

29. Vriesendorp TM, van Santen S, DeVries JH, de Jonge E, Rosendaal FR, Schultz MJ, et al. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med. 2006;34:96–101.

30. Gayat E, Piracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36:1993–2003.

31. Krinsley JS, Grover AG. Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Crit Care Med. 2007;35:2262–7.

32. Huang CL, Wu YW, Hsieh AR, Hung YH, Chen WJ, Yang WS. Serum adipocyte fatty acid-binding protein levels in patients with critical illness are associated with insulin resistance and predict mortality. Crit Care. 2013;17:22.

33. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187–95.

34. Goodman SN. Toward evidence-base medical statistics: 1: The P value. Ann Intern Med. 1999;130:995–1004.

35. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.

36. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180:821–7.

37. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009;301:1556–64.

38. Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong X, et al. Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change. Crit Care. 2008;12:R49.

39. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–9.
40. Ichai C, Preiser JC. International recommendations for glucose control in adult non diabetic critically ill patients. Crit Care. 2010;14:166.

41. Plummer MP, Bellomo R, Cousins CE, Anninck CE, Sundararajan K, Reddi BAJ, et al. Dysglycaemia in the critically ill and the interaction of the chronic and acute glycaemia with mortality. Intensive Care Med. 2014;40:973–80.

42. Macrea D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, et al. A randomized trial of hyperglycemic control in pediatric intensive care. N Engl J Med. 2014;370:107–18.
7,667 Patients assessed for eligibility

4,107 Excluded

2,684 Randomized

1,351 Randomized to undergo computerized tight glucose control
  16 Not retained in the analysis
  15 Withdrawn
  1 Lost to follow-up
  1,335 retained in the analysis

1,333 Randomized to undergo usual care conventional glucose control
  22 Not retained in the analysis
  21 Withdrawn
  1 Lost to follow-up
  1,311 retained in the analysis

2,646 Study cohort

47 discarded (blood glucose missing data)

2,601 Retained in the analysis

1,474 Control
874 Moderate hypoglycemia
253 Severe hypoglycemia
